Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial

ConclusionsDupilumab provided clinically meaningful improvements in signs, symptoms, and quality of life in adolescents with moderate-to-severe atopic dermatitis among patients with Investigator ’s Global Assessment>  1 at week 16. Treatment responses should be interpreted in the context of such clinically relevant patient-reported outcome measures.Trial RegistrationClinicalTrials.gov; NCT03054428.Video abstractAdolescents with atopic dermatitis: does dupilumab improve their signs, symptoms, and quality of life? (MP4  212916 kb)
Source: American Journal of Clinical Dermatology - Category: Dermatology Source Type: research